Corinne Savill's most recent trade in Cullinan Oncology Inc was a trade of 75,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 37,500 | 240,990 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 37,500 | 203,490 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 01 Feb 2024 | 40,000 | 165,990 | - | 16.2 | 647,200 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 40,000 | 70,331 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 01 Feb 2024 | 40,000 | 205,990 | - | 4.3 | 172,000 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 29 Jan 2024 | 40,000 | 205,990 | - | 4.3 | 172,000 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 14.09 per share. | 29 Jan 2024 | 40,000 | 165,990 | - | 14.1 | 563,600 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 26,003 | 110,331 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2024 | 13,997 | 0 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 22 Jan 2024 | 21,316 | 187,306 | - | 4.3 | 91,659 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.46 per share. | 22 Jan 2024 | 21,316 | 165,990 | - | 12.5 | 265,597 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 21,316 | 13,997 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.18 per share. | 22 Jan 2024 | 14,559 | 170,115 | - | 12.2 | 177,329 | Common Stock |
| Cullinan Oncology Inc | Savill Corinne | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 22 Jan 2024 | 14,559 | 184,674 | - | 4.3 | 62,604 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 14,559 | 35,313 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 22 Jan 2024 | 4,125 | 165,990 | - | 12.0 | 49,583 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 20,500 | 170,115 | - | 0 | Common Stock | |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Sale of securities on an exchange or to another person at price $ 15.22 per share. | 18 Jul 2022 | 14,958 | 149,615 | - | 15.2 | 227,661 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Sale of securities on an exchange or to another person at price $ 15.06 per share. | 18 Jul 2022 | 5,042 | 164,573 | - | 15.1 | 75,933 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.33 per share. | 11 Jul 2022 | 39,800 | 169,815 | - | 13.3 | 530,534 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.85 per share. | 11 Jul 2022 | 200 | 169,615 | - | 13.9 | 2,770 | Common Stock |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 33,000 | 33,000 | - | - | Stock Option (Right to Buy) | |
| Cullinan Oncology Inc | Corinne Savill | Acting Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2022 | 16,500 | 209,615 | - | 0 | Common Stock |